Neuren Reports Strong Royalty Growth as DAYBUE Sales Hit US$101.1 Million in Q3 2025.

Neuren Pharmaceuticals Limited (ASX: NEU) recorded a strong third quarter in 2025, supported by impressive sales growth of DAYBUE (trofinetide). The product achieved net sales of US$101.1 million, an 11% increase compared to Q3 2024 and 5% higher than Q2 2025. During the quarter, more than 1,000 patients received shipments for the first time, with rising adoption from community-based physicians. Neuren’s royalty income reached AU$16.4 million, up 24% year-on-year, with projected full-year royalties expected between AU$63 million and A$66 million, based on Acadia’s revised sales guidance of US$385–400 million. 

International progress continues, with a Phase 3 trial underway in Japan and patient access programs established across Europe, Israel, the Middle East, and Latin America. A regulatory opinion from the EU’s CHMP is anticipated in early 2026, underscoring DAYBUE’s expanding global footprint and Neuren’s strengthening royalty outlook.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com